Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
- Takeda’s Ramona Sequeira Becomes 1st Female PhRMA Chair
February 15, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- PhRMA Taps Diplomat Hans Klemm as New Japan Representative
February 3, 2022
- Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
- JPMA Embarking on Holistic Social Security Debate, Health Coverage Review: Chief
January 21, 2022
- CEA Process to Be Improved, but Operational Issues Remain: PhRMA/EFPIA
January 20, 2022
- JGA Chief Pledges to Restore Trust in Generics in 2022
January 14, 2022
- JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
January 14, 2022
- Osamu Kunii of Global Fund to Become New GHIT Fund CEO
January 13, 2022
- FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
- EFPIA Japan Taps Takeo Morooka as Director General
December 24, 2021
- Generic Use Rate Skids to 79.2% in July-September: JGA
December 24, 2021
- Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform
December 23, 2021
- INES Launches Cervical Cancer Awareness Project in Japan
December 10, 2021
- Study Group Launched by Drug Policy Veterans Pushes 6% Adjustment Rate
December 6, 2021
- JEMA Calls for Disclosure of Expected 3-Month Inventory Levels, Smaller Number of Companies per API
December 2, 2021
- Pharma, Wholesaler Leaders Hold 1st Meeting with PM Kishida
November 30, 2021
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…